IOVA · Iovance Biotherapeutics Inc
United States · RS rating 99 · As of 2026-10-14
| Price | 14.21 USD |
|---|---|
| 1-day change | -2.0% |
| RS rating (overall / 1M / 3M / 12M) | 99 / 98 / 98 / 99 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 56 / 56 / 65 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +28.0% |
| Sales growth Q/Q | +28.6% |
| Distance from 52-week high | +4.1% |
| Market cap (USD) | $1.4B |